Skip to main content

Advertisement

SpringerLink
Log in

Response to the letter to the editor of Lambros et al.

  • Letter to the Editor
  • Published:
Virchows Archiv Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sterlacci W, Fiegl M, Gugger M, Bubendorf L, Savic S, Tzankov A (2017) MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC. Virchows Arch 471:49–55

    Article  CAS  PubMed  Google Scholar 

  2. Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F, Akerley W, Orlov S, Santoro A, Spigel D, Hirsh V, Shepherd FA, Sequist LV, Sandler A, Ross JS, Wang Q, von Roemeling R, Shuster D, Schwartz B (2015) Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol 33:2667–2674

    Article  CAS  PubMed  Google Scholar 

  3. Kubo T, Yamamoto H, Lockwood WW, Valencia I, Soh J, Peyton M, Jida M, Otani H, Fujii T, Ouchida M, Takigawa N, Kiura K, Shimizu K, Date H, Minna JD, Varella Garcia M, Lam WL, Gazdar AF, Toyooka S (2009) MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer 124:1778–1784

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Spigel DR, Edelman MJ, O'Byrne K, Paz-Ares L, Mocci S, Phan S, Shames DS, Smith D, Yu W, Paton VE, Mok T (2017) Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung. J Clin Oncol 35:412–420

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Pathology, Klinikum Bayreuth, Preuschwitzerstrasse 101, 95445, Bayreuth, Germany

    William Sterlacci

  2. Institute of Pathology, University Hospital Basel, Schoenbeinstrasse 40, 4031, Basel, Switzerland

    Alexandar Tzankov & Spasenija Savic

Authors
  1. William Sterlacci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexandar Tzankov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Spasenija Savic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William Sterlacci.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sterlacci, W., Tzankov, A. & Savic, S. Response to the letter to the editor of Lambros et al.. Virchows Arch 471, 687–688 (2017). https://doi.org/10.1007/s00428-017-2230-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-017-2230-z

Search

Navigation